SCHEMBL6475263

SCHEMBL6475263

CCCCN(CCCC)c1ccc(CCc2ccc(N)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.56
▸ GFER P55789 2/20 0.52
▸ PSMD14 O00487 1/20 0.52
▸ ALDH1A1 P00352 1/20 0.52
▸ CYP3A4 P08684 1/20 0.52
▸ TSHR P16473 1/20 0.52
▸ MAPK1 P28482 1/20 0.52
▸ RECQL P46063 1/20 0.52
▸ TDP1 Q9NUW8 1/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.52
▸ MAOB P27338 4/20 0.44
▸ MAOA P21397 2/20 0.44
▸ HTR2A P28223 1/20 0.43
▸ NR1H2 P55055 1/20 0.40
▸ NR1H3 Q13133 1/20 0.40
▸ CYP19A1 P11511 2/20 0.40
▸ AOC3 Q16853 1/20 0.40
▸ CNR2 P34972 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL143242 0.91 CYP3A4 (0.61) MAPTGFERPSMD14ALDH1A1CYP3A4
Hydrochloric Acid SCHEMBL6657541 0.89 CYP3A4 (0.59) MAPTGFERPSMD14ALDH1A1CYP3A4
Hydrochloric Acid SCHEMBL5697631 0.89 CYP3A4 (0.59) MAPTGFERPSMD14ALDH1A1CYP3A4
SCHEMBL13949611 0.87 CYP3A4 (0.57) MAPTGFERPSMD14ALDH1A1CYP3A4
SCHEMBL27461663 0.85 CYP3A4 (0.55) MAPTGFERPSMD14ALDH1A1CYP3A4
SCHEMBL45791 0.85 CYP3A4 (0.59) MAPTGFERPSMD14ALDH1A1CYP3A4
SCHEMBL7932826 0.85 CA2 (0.47) MAPTALDH1A1CYP3A4TSHRHTR2A
SCHEMBL1498858 0.83 ALDH1A1 (0.57) MAPTGFERPSMD14ALDH1A1CYP3A4
SCHEMBL7771003 0.83 ALDH1A1 (0.57) MAPTGFERPSMD14ALDH1A1CYP3A4
SCHEMBL3691300 0.83 ALDH1A1 (0.57) MAPTGFERPSMD14ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6972287-B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits PFIZER INC. (US) 2005-12-06 — — US disclosed
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-11-04 — — US disclosed
EP-1225886-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2002-07-31 — — EP disclosed
WO-2000076489-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2000-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits APP, PSEN1, BACE1 MAPT 6/4885GFER 1977/4885PSMD14 1820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback